【效果】维利西呱能改善心力衰竭患者的生活质量

Heart failure is the final stage in the development of cardiovascular disease and is the leading cause of death in patients with cardiovascular disease. Vericiguat is a soluble guanylate cyclase stimulator with a unique mechanism for the effective management of patients with chronic heart failure following decompensation events. The drug specifically restores the damaged NO-sGC-cGMP pathway, which plays a key role in the progression and worsening of heart failure symptoms. (vericiguat) is primarily used to treat adult patients with symptomatic chronic heart failure.

Vericiguat treatment effects

The phase 3 clinical trial called VICTORIA is specifically designed to evaluate the use of drugs in people with exacerbation of chronic heart failure, high risk of cardiovascular death and repeated heart failure hospitalizations. The above patients are divided into two groups, receiving vericiguat treatment and placebo treatment respectively. The results at a median follow-up period of 10.8 months showed that the vericiguat treatment group reduced the risk of the composite end point of hospitalization for heart failure and death from cardiovascular causes compared with the placebo group, by 35.5% vs 38.5%.

VICTORIA's data has been published in the New England Journal of Medicine. The trial results show that vericiguat can improve patients' disease progression, reduce the patient's risk of the composite endpoint of hospitalization for heart failure and death from cardiovascular causes, and significantly improve their quality of life. The launch of this drug has brought new treatment options and options to many patients with heart failure.

The above is an introduction to vericiguat. If patients want to know other information about the drug (such as vericiguat price, purchase channels, usage, side effects, etc.), they can consult the medical companion travel service.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles